Recombinant factor VIIa

Apr 06, 2020

HEMA Biologics(TM) Announces FDA Approval of SEVENFACT® [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors

Apr 01, 2020

FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors

Feb 26, 2020

Hemophilia A - Forecasts for Seven Major Markets Covering the United States, EU5 and Japan

Jul 03, 2019

Easing the Burden for People with Hemophilia

Jul 01, 2019

CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019

Jun 26, 2019

Bayer to present new data from its hemophilia A portfolio at the International Society of Thrombosis and Haemostasis (ISTH) 2019 annual congress

Aug 30, 2018

Bayer Receives FDA Approval for Jivi®, New Hemophilia A Treatment With Step-Wise Prophylaxis Dosing Regimen

Dec 01, 2017

Asia-Pacific $1.49 Billion Hemophilia A and B Therapeutics Market to 2023

Oct 30, 2017

Bayer Announces BAY94-9027 Biologics License Application Accepted by U.S. Food & Drug Administration